Apellis Pharmaceuticals Profit Margin

Apellis Pharmaceuticals (APLS) currently reports a profit margin of 17.98% as of March 2026. That compares with -30.43% in the prior-year period — up 159.1% year over year. That is above the Healthcare sector average of 13.76%. Use the charts on this page to explore Apellis Pharmaceuticals's profit margin history and peer comparisons.

Apellis Pharmaceuticals's profit margin increased from -30.43% to 17.98% — a 159.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apellis Pharmaceuticals's profit margin of 17.98% is higher than the Healthcare sector average of 13.76%. That is roughly 30.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Apellis Pharmaceuticals's current 17.98% should be judged against Healthcare norms (sector average: 13.76%) and against APLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 17.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Apellis Pharmaceuticals, and consider following APLS for alerts when major investors trade the stock.